Rating: Cautious Bull | Target Price: HKD 21–25 | Current Price: HKD 15.18 (2026-11-06 close) | Margin of Safety ~38% (based on baseline fair value floor) | Time Horizon: 12–18 months
3SBio is in a transition period between "book prosperity inflated by Pfizer's upfront license payment" and "accelerating decline of legacy biologics": of the 2025 net profit attributable to shareholders of RMB 8.482 billion, approximately RMB 9.4 billion of revenue was one-time license recognition; the 2026 reported earnings will inevitably fall off a cliff (sell-side consensus net profit attributable of approximately RMB 2.4–2.8 billion, roughly -70% YoY), but this is mainly base effect and FX noise—2026H1 adjusted net profit was RMB 1.436 billion, +26.5% YoY, of which organic earnings excluding milestones actually declined about 37%, partially offset by a 25.3% contraction in absolute expense levels. At the current price of HKD 15.18, the market cap is HKD 38.16 billion, while net cash of approximately RMB 17.97 billion (approximately HKD 8.43 per share, 55.5% of the share price) has not been fully priced in by the market; enterprise value (EV) of approximately RMB 14.4 billion corresponds to only about 10x recurring earnings, and the implied value of the remaining SSGJ-707 milestone pool (approximately USD 4.68 billion) and the autoimmune pipeline approaches zero. We estimate fair values under bear/base/bull scenarios of HKD 13.5–16 / 21–25 / 28–36; the current price is nearly equal to the bear-case fair value midpoint (HKD 15.4), with a probability-weighted expectation of approximately HKD 23.4 (+54.4% vs. current price)—odds are significantly asymmetrically skewed positive. Key constraints: the erosion from biologics sales at -19.3% has not yet bottomed, the pace of Pfizer milestone triggers is not under the company's control, FX volatility on approximately RMB 9.7 billion of foreign currency deposits has become routine, and the shareholder base has not fully cleared—hence the rating is Cautious Bull rather than Firm Bull. The ivonescimab FDA decision on 2026-11-14 and the HARMONi-3 final readout at the end of 2026 are the largest two-way events in the coming month.
Nature of the opportunity: Undervaluation + event options, not trend confirmation. The next 6–18 months feature a dense, falsifiable catalyst chain: the ivonescimab (same-mechanism first-mover drug) FDA PDUFA decision on 2026-11-14 → the 2026 NRDL at the end of November (first-round national negotiation for TPIAO new formulation / Yisaipu new formulation) → HARMONi-3 squamous cohort final readout in 2026Q4–2027Q1 → Pfizer's launch of the EC/UC two global Phase III trials and milestone payment confirmation in 2026H2 → the 611 (IL-4R) and semaglutide weight-loss NDA approval windows in 2027.
Primary share price driver: The pace of Pfizer's 707 milestone realization—the only cash flow with quasi-recurring attributes under the current valuation and the anchor for option pricing. Tracking signals are the incremental "license revenue" line in interim/annual reports and new Phase III registrations of PF-08634404 on ClinicalTrials.gov.
Demonstrable expectation gap: Reverse decomposition at the current price shows the market assigns a very low combined value to the remaining 707 options and the autoimmune pipeline (≤ approximately RMB 4.6 billion), while the milestone of RMB 852 million has already been received and recognized in 2026H1, and Pfizer has initiated 9 global multi-center clinical trials. To be candid: this residual can also be partially explained by alternatives such as a systematic correction in Chinese pharma stocks listed in Hong Kong or a discount on net cash (the fact that 3SBio's share price did not re-rate after AstraZeneca announced a USD 2 billion stake in Summit in 2026-09 is corroborating evidence). The realization of the expectation gap depends on the company's own milestone receipts and pipeline data, not merely on "market awakening."
Primary falsification risk: Accelerating legacy erosion (biologics decline in the 2026 annual report worse than -18%~-20%) and 707's key Phase III failure/Pfizer slowdown—if either materializes, valuation will switch to "declining pharma" pricing (approximately the HKD 10–13 zone). Evidence strength rating B (first-hand financials + cross-verification from multiple named sell-side sources, but 707 peak sales and NRDL price-cut magnitude rely on inference).
At the current price of HKD 15.18, the market cap is HKD 38.16 billion (approximately RMB 32.36 billion); after subtracting net cash of RMB 17.97 billion, EV is approximately RMB 14.39 billion, corresponding to about 10.1x recurring adjusted net profit (annualized approximately RMB 1.425 billion); if organic earnings decline to RMB 1.0 billion per the erosion scenario in Thesis 4, the same EV corresponds to approximately 14.4x—both measures are within the valuation band of mature pharma companies, while the remaining USD 4.68 billion 707 milestone pool, discounted at a neutral 35% realization rate, is worth approximately RMB 12.2 billion, or nearly 85% of the entire current EV. Reverse sensitivity: even valuing net cash at a 30% discount, the baseline SOTP is still approximately HKD 21.0 (+38% vs. current price); under the scenario of recurring earnings falling to RMB 1.0 billion, approximately HKD 22.1. The conclusion is insensitive to the specific attribution of "why the market applies a discount"—whether the explanation is options at zero, sector beta, or a cash discount, the current price represents a 38%–64% discount to baseline fair value.
The 2026H1 adjusted net profit growth of +26.5% was almost entirely driven by the 707 milestone (approximately RMB 724 million after tax) and interest income (RMB 223 million, +166% YoY): excluding milestones, organic adjusted profit was approximately RMB 712 million, down about 37% from RMB 1.136 billion in 2025H1 (corroborated by CMB International's measure of "recurring operating profit excluding licensing and FX, -32%"). The true operating picture is: biologics sales of -19.3% (organic pressure) coexisting with an absolute decline in selling expenses of -25.3% (cost reduction and efficiency gains), with the selling expense ratio falling from 37.1% to 26.7% (of which about 4.3 percentage points is a mathematical effect of licensing revenue inflating the denominator). Management's official attribution of the biologics decline is "NRDL policy, centralized procurement, and VAT policy adjustments"—the VAT rate change (3%→13%) is a one-time channel disruption whose share awaits quantitative separation in the 2026 annual report.
The remaining milestone pool is approximately USD 4.68 billion (USD 4.8 billion minus the recognized portion); the company's accounting policy states explicitly that "future clinical development milestone payments are not within the Group's control and are therefore not regarded as highly probable until achieved"—this is the key to understanding this thesis: each new Phase III Pfizer launches (EC and UC two trials planned for 2026H2) may trigger a non-refundable payment (Citi expects over USD 100 million to be recorded in 2026H2), but the timing and amount are decided by Pfizer, and are linked to the ivonescimab FDA decision on 2026-11-14 and HARMONi-3 data. Milestone cash flow is a high-probability floor for valuation and profit, and must be managed as a conditional option rather than a receivable.
Structurally: TPIAO's share of the thrombocytopenia treatment market fell from 66.2% (2024H1) to 60.4% (2025, IQVIA sales basis; volume share only 27.7%), with oral TPO-RA substitution siphoning share; rhEPO's post-VBP share of 39.6% continues to decline; Yisaipu's TNF-α class faces a provincial-alliance VBP expansion leaked in 2026-09 (draft circulated with 7 products in the first batch including infliximab, to be verified). Stress test: if biologics revenue falls another 15%–25% in 2027, with linked expense contraction, recurring net profit attributable would fall to RMB 0.9–1.1 billion (the extreme scenario of RMB 0.4–0.6 billion implies completely rigid expenses, inconsistent with the demonstrated 25.3% selling expense contraction in 2026H1, and thus of low probability). Hedging evidence is also accumulating: 608 (IL-17, 2026-02), 613 (IL-1β, 2026-08), and eltrombopag (2026-03) approved within the year; TPIAO new formulation / Yisaipu new formulation entering national negotiation; TPIAO CLDT indication approved in 2025-12 with FDA approval for an overseas bridging trial.
Cumulative buybacks in 2026 of approximately 25.11 million shares for approximately HKD 392 million (about 1.0% of market cap), combined with the Chairman's increase, constitute a "industrial capital + controlling shareholder" bottom signal; but the magnitude must be acknowledged: buybacks at about 1% of market cap, the increase at about 0.04% of market cap, and the 2025 cash dividend payout ratio fell to about 6.5% (dividend per share flat at HKD 25 cents for three consecutive years). Until the dividend/buyback ratio rises to the ~5%-of-market-cap level or a capital return framework is introduced, "net cash = floor" is merely a value reference, not a verifiable price support mechanism—the 2026-11-04 close of HKD 14.75, already about 8% below the Chairman's September purchase price, is the test. The gearing ratio of 13.5% and no refinancing pressure are hard facts.
Each 1% appreciation of RMB erodes approximately RMB 97 million of profit. This exposure stems from the retention of Pfizer's USD payments and represents unrealized deposit revaluation; but two points must be presented honestly: first, the company's adjusted profit excludes the FX loss of RMB 503 million yet retains the interest income of RMB 223 million (+166% YoY) generated by the same deposits—an asymmetric treatment favoring the company; second, against the backdrop of continued RMB appreciation within 2026, the shrinking RMB value of foreign currency deposits is a real erosion of net assets rather than pure "noise"—the company's derivative assets are only RMB 58 million, with no disclosure of material hedging. Management stated in the announcement that it "expects that RMB exchange rate fluctuations will not have a material adverse effect on the Group's operations in the foreseeable future." This factor will continue to reinforce the market's discount on the "unpredictability" of reported earnings until the company proactively converts currency or introduces hedging.
| Metric (RMB 100M) | 2023FY | 2024FY | 2025FY | 2026H1 (latest period) | 2026H1 YoY |
|---|---|---|---|---|---|
| Revenue | 78.16 | 91.08 | 176.96 | 45.26 | +3.9% |
| Net profit attributable to shareholders | 15.49 | 20.90 | 84.82 | 11.47 | -15.6% |
| Adjusted net profit (Non-GAAP) | 19.52 | 23.19 | 84.54* | 14.36 | +26.5% |
| Gross margin | 84.98% | 85.95% | 92.38% | 83.8% | -1.5pct |
| Net margin (attributable basis) | 19.82% | 22.95% | 47.93% | 25.3% | -5.9pct |
| Operating cash flow | 20.83 | 32.01 | 96.69 | 8.99 | -7.2% |
| Free cash flow (OCF − PP&E purchases) | 13.79 | 22.38 | 91.28 | 6.54 | — |
| Cash-like assets + wealth-management products | 49.00 | 43.49+— | 165.34+38.58 | 141.65+51.27 | — |
| Interest-bearing debt | 48.00 | 35.07 | 25.54 | 13.21 | -48.3% |
| Gearing ratio | 30.10% | 25.51% | 16.04% | 13.53% | — |
*2025 adjusted net profit still contains a large one-time licensing profit and is not comparable; the organic measure of 2026H1 adjusted profit excluding milestones is approximately RMB 712 million (our estimate). Cash-like assets = cash and equivalents + unsecured/pledged time deposits (wealth-management products not separately listed in 2023/2024); net cash as of 2026-06-30 was approximately RMB 17.971 billion (cash-like assets + wealth-management products − interest-bearing debt). The company has no net debt/EBITDA concept (net cash position).
Reasons for metric changes (items with YoY ≥ ±20%): ① 2025 revenue +94.3%, net profit attributable +305.8%, gross margin rising to 92.4%, income tax +230.1%—all due to the one-time point-in-time recognition of Pfizer's 707 upfront payment + option fee of RMB 9.426 billion (recognized at the point of license delivery under IFRS 15, as explicitly stated by management in the annual report MD&A), unsustainable; ② 2026H1 biologics sales -19.3%—management attributes this to "NRDL policy, centralized procurement, and VAT policy adjustments"; ③ 2026H1 licensing revenue +RMB 852 million (zero in the prior-year period)—development milestones triggered by Pfizer's clinical advancement; ④ 2026H1 selling and distribution expenses -25.3% (expense ratio 37.1%→26.7%)—cost reduction and efficiency gains; ⑤ R&D costs +24.9%—"accelerated R&D progress" (fully expensed); ⑥ 2026H1 other income and gains net fell RMB 482 million YoY—net FX loss of RMB 503 million (revaluation of large foreign currency deposits); ⑦ 2025 cash and equivalents rose from RMB 1.218 billion to RMB 12.177 billion—receipt of Pfizer upfront payment + equity financing of approximately HKD 3.94 billion, alongside repayment of RMB 1.2 billion panda bonds and RMB 3.095 billion of bank borrowings.
2026H1 revenue was RMB 4.526 billion, +3.9% YoY: structurally, this is the offsetting result of "biologics -19.3% (RMB 3.443 billion) + milestone +RMB 852 million + CDMO +160.9% (RMB 231 million)"—licensing and CDMO (including 707 drug substance supplied to Pfizer) masked the contraction in organic drug sales. Net profit attributable was RMB 1.147 billion, -15.6%, mainly due to non-operating FX losses of RMB 503 million (without which attributable profit would have been approximately RMB 1.65 billion, +21% YoY); adjusted net profit was RMB 1.436 billion, +26.5%, but excluding milestones, organic profit was approximately RMB 712 million, down about 37% YoY (see Thesis 2 for details). Gross margin was 83.8% (-1.5pct); cost of sales +14.3% due to increased 707-related production costs. Operating cash flow was RMB 899 million (-7.2%), OCF/attributable profit of 0.78; accounts receivable grew only 6.4% (81% within 2 months of aging), with no signs of accumulation. No interim dividend. Market reaction: the share price rose about 5% the day after the announcement; subsequently 6+ sell-side firms (CICC, CMB International, Citi, BOCOM, CLSA, Morgan Stanley) maintained Buy/Overweight ratings, but broadly cut target prices (CICC -18% to HKD 30, Citi 36→34.4, BOCOM/CLSA approximately 30–30.4)—a combination of "acceptable results, downward earnings revisions," mutually corroborating the stock's grinding decline. Against sell-side consensus (2026E attributable net profit of approximately RMB 2.4–2.8 billion), the full-year reported results will still show a cliff of roughly -70% YoY—this is a high-base collapse already fully priced in by the market. The true marginal information lies in 2026H2: the biologics decline after digestion of the VAT disruption, the EC/UC Phase III launches and corresponding milestone recognition, and the year-end national negotiation results.
Business model: A hybrid pharma company combining cash-cow exclusive products + CDMO + "full-monetization" out-licensing. Domestically, a sales force of ~2,867 covers nearly 10,000 hospitals. TPIAO is the only commercialized rhTPO globally (20 years of process exclusivity, zero price cut in the 2024 NRDL renewal); rhEPO's dual brands rank #1 in combined share; Mantidi dominates the minoxidil market. The innovative asset SSGJ-707 has been licensed globally (including a mainland-China commercialization option) to Pfizer, with the company receiving "upfront + milestones + double-digit royalties + manufacturing profit (CDMO-supplied drug substance)"—compared with Akeso's high-risk, high-retention model of "self-operating China + Summit taking the rest of the world," 3SBio chose certainty upfront, giving up upside elasticity from volume ramp. Recurring revenue share: ~81% in 2026H1 (drug sales + CDMO), only 47% in 2025 (one-time licensing was 53%).
Cash content of earnings: OCF/attributable net profit for 2023–2025 was 1.34 / 1.53 / 1.14, and 0.78 in 2026H1 (half-year figure, no receivables build-up, mainly higher other operating payments); FCF/attributable net profit 0.89 / 1.07 / 1.08 / 0.57 (2026H1 is a half-year figure and should not be annualized). Long-term, cash conversion of book profits is healthy—over a five-year horizon there is no "profit turning into receivables" or "being swallowed by CapEx." Recurring earnings test: of the 2025 headline attributable profit of RMB 8.482bn, ~RMB 9.4bn of licensing revenue (pre-tax) was one-time; the core earnings run-rate is roughly RMB 1.4–3.0bn/year (organic decline + milestone volatility)—this is precisely the source of valuation disagreement. Non-GAAP stringency: add-backs are mild (SBC in 2026H1 only RMB 47m, 4.1% of attributable profit, not aggressive), but adjusted figures exclude FX losses while retaining foreign-currency interest income—an asymmetry (see Argument Six).
Return on capital: ROIC estimated at ~10.3% for FY2024 (NOPAT RMB 2.179bn / invested capital RMB 21.59bn); excluding licensing revenue, annualized ~7.4% for 2026H1—the existing business's return on capital is roughly in line with the ~10.5% cost of equity—hardly a "money-printing machine," but assets are extremely light (intangibles + goodwill only 16.7% of total assets) and RMB 18bn of net cash means it barely needs external capital.
CapEx quality: CapEx/depreciation for 2023–2025 was 1.78 / 1.65 / 0.76—the first two years reflected construction of the Northern Pharma Valley CDMO base; 2025 turned to contraction, and the company guides CapEx of only RMB 1.0–1.2bn over the next three years (mostly maintenance), with clear FCF release capacity.
Red flags: ① In 2025 a single customer (Pfizer) accounted for 53.7% of revenue (vs. 3.8% the prior year)—a structural jump, transparent but with a volatile base; ② payout ratio fell continuously from 35.2% → 26.1% → 6.5%, with DPS unchanged for three years (25 HK cents); ③ in the record-profit year, cash returns diverged from profit. There are no classic red flags such as "good book numbers, bad cash flow" or "persistent financing dilution" (the two 2025 financings were Pfizer's strategic subscription + a voluntary placement, totaling ~4.5% of share capital; ~1% offset by 2026 buybacks).
Say-do consistency: pragmatic, delivery-oriented. Three checks: ① The 2024 annual report pledged "a key new drug entering commercialization every year from 2025" → Xinbi'ao/eltrombopag approved in 2025, 608/613 approved in 2026—delivered; ② The 2024 annual report pledged "continuing to out-license quality pipeline assets" → 707 licensed to Pfizer in 2025 (USD 1.25bn upfront, a record for Chinese innovative drug out-licensing; total up to ~USD 6.3bn)—delivered beyond expectations; ③ The 2025 annual report: "semaglutide weight-loss indication NDA to be filed soon" → accepted in July 2026—delivered. The only discount: the Chairman's statement says "sharing development dividends with shareholders," yet payout fell to 6.5%—nominally delivered, substantively watered down.
Shareholder friendliness: neutral to conservative. DPS flat at 25 HK cents/share for three consecutive years (~HKD 550m/year); a cancellation-style buyback of HKD 266m in 2024; buybacks resumed in 2026 at ~HKD 392m (held as treasury shares, not cancelled); offsets: two equity financings in 2025 diluted ~4.5% (Pfizer's 1.28% being strategic binding; the December placement at 4.14%, HKD 29.62, now deeply underwater). With RMB 18bn of net cash, capital return intensity clearly falls short of capacity.
Risk signals: ① Chairman and CEO roles combined in Lou Jing (deviation from Corporate Governance Code C.2.1 for two consecutive years; the company provided explanations); ② auditor changed from EY (10+ years' tenure) to KPMG (approved at the 2026 AGM); the company disclosed no disagreements and attributed it to routine rotation, but it coincides with a period of dramatic revenue-structure change—optically it constitutes governance noise; ③ associates' P&L swung from +RMB 351m to -RMB 103m in 2025, a RMB 453m swing unexplained separately in the annual report.
| Segment | 2026H1 revenue share | YoY | One-line business logic |
|---|---|---|---|
| Biologic drug sales (TPIAO/rhEPO/Yisaipu/Qipting/Mantidi etc.) | 76.1% | -19.3% (FY2025 -10.3%) | In-hospital prescription drugs suppressed by VBP/NRDL; Mantidi OTC e-commerce is the bright spot; the company has stopped disclosing single-product revenue |
| Out-licensing revenue (707→Pfizer) | 18.8% | +852m (prior-year 0) | One-time upfront/options + subsequent milestones and royalties, non-recurring, near-100% gross margin |
| CDMO (Desheng/Shengguo/Guangdong 3SBio/Sirton) | 5.1% | +160.9% | Order-driven, includes supplying 707 drug substance to Pfizer and technical support—same origin as the licensing deal |
Profit engine: in 2025 the bulk of headline profit came from licensing (one-time); from 2026H1 the structure returns to biologic drug sales as the profit base with milestones as incremental elasticity; CDMO grows fastest but is small. Gross margin structure: consolidated GM 83.8%; licensing near 100%, biologics in the 85–86% band, CDMO not separately disclosed—the gap mainly reflects the fundamental difference between "selling molecules" vs. "selling products," not deteriorating pricing power. Share benchmarks (IQVIA, 2025): TPIAO holds 60.4% of the thrombocytopenia treatment market (27.7% by volume, average price far above oral TPO-RA); rhEPO combined 39.6%; Mantidi ~70% of minoxidil (2021 media figure, to be verified). Note: TPIAO's high value share but low volume share means its moat comes from the exclusive injectable form and NRDL access, with oral substitutes eroding the volume base from the low-price side.
Accounting red flags: ① One-time recognition of licensing upfront at a point in time (IFRS 15-compliant, but makes 2025 headline revenue/net margin non-comparable; severity: medium)—"the upfront and option fees received, most of which have been recognized as licensing revenue"; ② concentrated recognition of FX losses on large foreign-currency deposits at period-end (treasury P&L distorting operating profit; medium)—2026H1 net FX -RMB 503m; ③ customer concentration jumped from 3.8% to 53.7% within one year (Pfizer deal, transparently disclosed; medium); ④ auditor change (EY→KPMG, explained by the company as 15-year tenure rotation, no disagreements; low); ⑤ 2025 share-based compensation of RMB 223m (vs. 32m prior year) excluded from adjusted figures (2.6% of attributable profit, not an aggressive口径; low).
Cross-period consistency: ① Biologics sales growth +16.8% → -10.3% → -19.3% consistent with management's explanation (VBP/NRDL/VAT); ② payout ratio 35.2% → 26.1% → 6.5% inconsistent with the "sharing development dividends" rhetoric—with net profit +306%, DPS frozen for three years is a point where words and actions diverge; ③ OCF/attributable 1.34 → 1.53 → 1.14 → 0.78 shows no deterioration and is consistent with operating explanations; ④ receivables match revenue: 2025 receivables -17.1%, 2026H1 +6.4%, no build-up; the company did not explain and did not need to (normal). Overall conclusion: based on the 2023–2026H1 financials extracted here, no manipulative accounting traces found; the main issues are comparability disruption from the dramatic revenue-structure change and treasury P&L noise, both made explicit in the text.
Current market data: share price HKD 15.18 (2026-11-06 close), 2.514bn shares outstanding (ex-treasury), market cap HKD 38.16bn; net cash RMB 17.97bn (2026-06-30, ~HKD 8.43/share, 55.5% of share price); EV ~RMB 14.39bn. FX: RMB 1 = HKD 1.1791, USD 1 = RMB 6.6647 (2026-11-07). Average daily turnover ~HKD 200–400m (~0.6–1.0% of market cap), liquidity normal.
Multiples and percentiles: PE(TTM) 4.0x (1st percentile over 5 years)—percentiles are indicative only: TTM earnings are severely polluted by the RMB 9.4bn one-time licensing income; a mechanical percentile carries no cheapness/expensiveness signal; PB 1.20x (50th percentile over 5 years, 45th over 3 years) is the most reliable relative anchor; EV/annualized recurring adjusted net profit ~10.1x; forward PE (2026E adjusted ~RMB 2.4–2.7bn) ~12.7x, ~5.6x on an EV basis. Peer benchmarking (PB as the key multiple, since peers' PE is mostly distorted by one-time BD items or losses):
3SBio's PB is the lowest among comparables, and over half its book equity is net cash—the implied pricing of operating assets is even lower; CSPC (PE TTM ~11.4x, a similar "legacy pressure + BD hedge" structure) is the closest mature-pharma anchor to 3SBio.
Market-implied expectations: reverse decomposition—market cap HKD 38.16bn − net cash HKD 21.19bn = EV HKD 16.97bn (~RMB 14.4bn). Two equivalent readings: ① the recurring business is priced at ~10x as a mature pharma, with the remaining 707 milestones/royalties, the autoimmunity pipeline, and the Mantidi spin-off jointly implied at near zero; ② 8x recurring + only the most conservative option pricing for 707. In one sentence: the current price demands "near-total failure of Pfizer's global Phase III matrix or a deep discount on net cash," while in reality 2026H1 milestones already delivered RMB 852m and Pfizer's Phase III matrix is still expanding. Alternative explanations must be considered side-by-side: after AstraZeneca announced a USD 2bn investment in Summit in September 2026, 3SBio's shares did not re-rate, indicating the discount also reflects sector beta and the common mid-cap net-cash discount in HK equities—but even if fully attributed to common discounts, the gap between the neutral rNPV (~RMB 12.2bn) and the residual at the current price remains enormous.
Three-layer value (EPV): asset value (net cash) ~HKD 8.43/share—an independent floor reference; EPV with zero growth ~HKD 4.47/share (normalized FCFE midpoint ~RMB 1.0bn/year: 2026H1 adjusted annualized ex-milestones RMB 1.425bn − maintenance CapEx ~RMB 400m + interest income; cost of equity 10.5%, equity basis); current price HKD 15.18 − EPV HKD 4.47 = growth-option residual ~HKD 10.71/share, 70.5% of the current price—the dominant value component of the current price is the growth option (707 royalties + autoimmunity pipeline + semaglutide + Mantidi spin-off), not the zero-growth asset. This contradicts the stereotype that "the market only pays for zero growth": the market did pay, but far below what the neutral scenario warrants. Growth-quality gate: existing ROIC (~10%) is roughly in line with the cost of equity (10.5%)—on the existing business alone this is not a "quality growth stock," but the 707 option's distinctiveness lies in its "semi-realized" nature (USD 1.4bn already banked; Phase III funded by Pfizer), with near-zero capital consumption and 2–3 year duration—option quality is acceptable.
Three scenarios and odds (SOTP/rNPV details in section 6.7 pipeline):
| Scenario | Probability | Fair range | vs. current | Swing factors |
|---|---|---|---|---|
| Bear | 22% | HKD 13.5–16 | -11% to +5% | Biologics -15%~-20% persists through 2028 + 707 key Phase III failure/slowdown (rNPV collapsing to ~RMB 5.6bn) + Mantidi spin-off shelved |
| Base | 53% | HKD 21–25 | +38% to +65% | Biologics stabilizing in 2027 (new products as hedge + NRDL negotiations concluded) + milestones continuing (707 neutral rNPV ~RMB 12.2bn) + Mantidi spin-off in 2027 |
| Bull | 25% | HKD 28–36 | +84% to +137% | 707 ex-China data beat, peak revised up to USD 5bn-class (rNPV ~RMB 20.3bn) + autoimmunity portfolio signs another MNC BD + Mantidi lists at a high valuation |
Probability-weighted expectation ~HKD 23.4 (+54.4% vs. current); the current price sits within the bear-case fair range (bear-case midpoint HKD 14.75, -2.8% vs. current)—the distribution is clearly skewed to the upside: to bear-case midpoint -2.8%, to base-case midpoint +51.5%, to bull-case midpoint +110.8%. External benchmarks: lowest sell-side target HKD 17.03 (unnamed aggregator), CICC's revised-down HKD 30, mean HKD 33.65—our base range is below the sell-side mean, because we apply 10x to the recurring business (not a DCF terminal approach) and take the conservative USD 3bn tier for 707's peak. Sensitivity: pricing net cash at 70% → base ~HKD 21.0 (+38%); recurring profit down to RMB 1.0bn → ~HKD 22.1 (+46%)—the conclusion is robust even to the harshest cash-discount assumptions.
Our forecasts vs. management/sell-side:
| Period | Our revenue (RMB bn) | Our attributable profit (RMB bn) | Sell-side consensus (CICC, revised down 2026-08-24) | Management guidance |
|---|---|---|---|---|
| FY2026E | 8.4–9.0 | 2.3–2.8 | Attributable 2.842 | Qualitative: more new launches in H2, advancing late-stage pipeline, continued BD |
| FY2027E | 8.8–9.8 | 2.6–3.2 | Attributable 3.051 | No quantitative guidance |
Our figures are ~8–19% below sell-side, mainly on more conservative H2 milestone recognition timing and FX. Conclusion: undervalued, target price HKD 21–25 (base-case fair value), ~38% margin of safety—the separation between quality (thick cash, real earnings, good delivery track record) and price (bear-case pricing) is the core judgment of this coverage.
Industry space. 3SBio's true battlefield is the combination of four business lines, spanning four markets of vastly different sizes. ① The global PD-(L)1 immune checkpoint market: approximately USD 52 billion in 2023 (Keytruda alone generated USD 25.0 billion in 2023 and USD 29.5 billion in 2024, per Merck's financial reports), accounting for about 23% of global oncology drugs; expected to exceed USD 90 billion by 2028 (Haitong International/MobStat consulting estimates); China's PD-1/PD-L1 market was approximately RMB 52.7 billion in 2024, up 44% YoY (Gongyan estimate, to be verified). ② Next-generation PD-1/VEGF bispecific antibodies: global sales of nearly USD 10 billion in 2025, projected to reach USD 52 billion by 2035, CAGR of about 18.5% (PharnexCloud citing industry forecasts; aggregate estimates serve only as cross-references); the global bispecific antibody market overall is expected to surpass USD 80 billion by 2030 (cited by Shanghai Securities weekly). ③ China rhTPO/thrombocytopenia: TPIAO generated RMB 5.06 billion in sales in 2024 (company annual report), holding 60.4% of the domestic thrombocytopenia treatment market (IQVIA 2025); post-VBP the national rhEPO market is around RMB 2 billion/year and shrinking. ④ Hair loss and weight-loss consumer healthcare: China has over 250 million hair-loss sufferers (National Health Commission); the anti-hair-loss drug market was about RMB 8 billion in 2023, with minoxidil-class products accounting for roughly 60% (cited by PharmaCube); per Frost & Sullivan, the approved AGA drug market grew from RMB 1.4 billion in 2017 to RMB 6.4 billion in 2030; China's GLP-1 weight-loss market is expected to exceed RMB 170 billion before 2030 (2024 reporting basis).
Quantified chain of demand inflection (structural). The biggest industry variable in this cycle is not natural growth, but the immunotherapy paradigm shift driven jointly by Keytruda's US core patent expiry in 2028 and the efficacy bottleneck of PD-1 monotherapy (first-line PD-L1+ NSCLC monotherapy ORR of about 39%): PD-1/VEGF bispecifics replace "IO + bevacizumab combination" with "dual IO + anti-angiogenic mechanisms in one molecule," improving both efficacy and economics — ivonescimab's HARMONi-2 head-to-head against Keytruda delivered PFS HR 0.59 (the world's first Phase III to defeat Keytruda), and the WCLC 2026-updated HARMONi study showed mOS of 30.8 vs 22.6 months; 707's Phase II ORR was 62% in the 10 mg/kg arm and 55% in the 20 mg/kg arm (non-head-to-head, lower evidence grade than ivonescimab). Penetration pace: ivonescimab has launched in China with two approved indications and has treated over 60,000 patients cumulatively; its first US PDUFA date is 2026-11-14; 707's domestic Phase III began in 2025-05, with Pfizer advancing 8-9 Phase III trials overseas; commercial penetration is expected from 2028. MNCs have backed this inflection with real money: Pfizer–3SBio (USD 1.25 billion upfront), BMS–BioNTech (EUR 11.1 billion scale), AstraZeneca–Summit (USD 2 billion equity investment), Innovent–Pfizer (USD 10.5 billion partnership), CSPC–AZ (USD 18.5 billion) — buyer competition has pushed the price for top-tier Chinese molecules to a historical peak (China innovative drug out-licensing deals totaled roughly USD 110 billion in 2026H1, per Shanxi Securities).
Industry chain and value distribution. Up/mid/downstream: upstream media/fillers/equipment dominated by Sartorius and Cytiva; 3SBio's vertically integrated in-house manufacturing (six major sites in Shenyang/Shanghai/Hangzhou/Shenzhen/Como, Italy) gives it weak bargaining power against upstream but high self-sufficiency, with 85%+ gross margin — the highest tier in the industry; midstream R&D–manufacturing–registration is driven by 3SBio's own platforms plus BD in-licensing; downstream bargaining power against hospitals/NHSA is tiered — TPIAO, as a sole-source product, achieved 2024 NRDL renewal with zero price cut (strong); EPO/Yisaipu are VBP products (weak); Metandi has brand pricing power with C-end consumers; vis-à-vis Pfizer, 3SBio is a price taker but has locked in an "upfront + milestones + royalties + drug substance supply" structure. The essence of value distribution in the license-out model: the bulk of overseas gross profit goes to the MNC, while the Chinese molecule owner earns certainty-front-loaded license fees plus royalty cash flows — asset-lighter than the Akeso model, with a capped ceiling. Gross profit retention: domestic product gross margins of 85%+ fully accrue to 3SBio; for 707 overseas, 3SBio receives double-digit royalties plus manufacturing profit.
Supply-demand and competitive landscape. PD-1/VEGF bispecifics currently show "excess clinical supply, zero commercial supply": apart from ivonescimab, none is commercialized; multiple molecules launching simultaneously from 2027-2028 will trigger price wars — a long-term risk certain to materialize in 3-5 years, not yet present. Over 20 domestic PD-1 monoclonals exist, with annual treatment costs compressed to RMB 30,000–50,000 — the red-ocean dynamic validates the necessity of iteration. rhTPO TPIAO holds category exclusivity, but oral TPO-RAs (eltrombopag, etc., including 3SBio's own product) divert demand from the substitution side; EPO is squeezed by VBP; Yisaipu's TNF-α class faces inter-provincial alliance procurement (rules leaked 2026-09, first batch of 7 monoclonals, unverified); minoxidil solution has 8 approvals and 40 pending applications (Pharmaron Cloud), with generic supply flooding in. Concentration: PD-1/VEGF shows a "first-mover duopoly" — Akeso/Summit (furthest progress) and Pfizer/3SBio (broadest Phase III footprint) lead; BMS/BioNTech form the third tier; Merck is on the sidelines (betting on TROP2 ADC). Entry barriers: the capital and execution hurdles of Keytruda head-to-head Phase IIIs (Summit's operating expenses for a single molecule were USD 1.09 billion/year) plus MNC-grade global registration channels.
Cycle and regulation. Industry position: early upcycle of IO 2.0 plus a historic-peak BD out-licensing channel, overlaid with the maturity-decline phase of legacy products (TPIAO/EPO/Yisaipu) — 3SBio overall sits in the transition zone of "old cash cows peaking, new value curve not yet realized," which is precisely the industrial backdrop for the stock's halving. Leading indicators: ① ivonescimab FDA PDUFA (2026-11-14); ② HARMONi-3 squamous cohort final PFS readout + interim OS (2026Q4–2027Q1; note the cautionary tale of its 2026-04 interim analysis failing to reach statistical significance and Summit's single-day -25% drop); ③ Pfizer 707 milestone payment cadence; ④ the 2026 NRDL + commercial insurance list (to be published end of November 2026). The regulatory direction is neutral-to-positive: the dual-track NRDL + commercial insurance system is taking shape (first-tier Class C list of 19 drugs effective 2026-01-01, with "three exclusions" protections, opening a channel outside national reimbursement negotiations for high-priced innovative drugs); on the negative side, VBP/alliance procurement continues to routinely squeeze legacy biologics (CSPC's oncology segment falling -50% in 2025 is the cautionary example).
Peer benchmarking:
| Company | Revenue scale | Growth | Gross margin | ROE/Profitability | Key difference vs 3SBio |
|---|---|---|---|---|---|
| 3SBio | RMB 17.70 billion in 2025 (approx. RMB 8.27 billion excluding licensing) | Organic approx. 0%~-19% | 85-86% | 2026H1 net profit RMB 1.15 billion, adjusted RMB 1.44 billion | Baseline: cash-cow sole-source products + full-monetization BD |
| Akeso 09926 | Approx. RMB 3.06 billion in 2025 | +43.9% (2026H1 +27.9%) | 79.4% (2025H1) | 2025 net loss of RMB 1.11 billion | Ivonescimab furthest globally; self-operated in China + high risk/high retention; P/S approx. 22x |
| Innovent 01801 | Surpassed RMB 10 billion in 2025; RMB 8.62 billion in 2026H1 | 2026H1 +44.8% | 85.5% (Non-IFRS) | 2026H1 net profit RMB 1.25 billion (+50%) | Fully self-operated volume growth + GLP-1 dual engines; 2030 target of RMB 35-40 billion; P/S approx. 8x |
| CSPC 01093 | RMB 26.01 billion in 2025 | -10.4% | 65.6% | 2025 net profit -10.3% | Legacy pharma hit hard by VBP, with ADC/BD filling in growth; PE TTM 11.4x — 3SBio's most comparable valuation anchor |
Company positioning in the industry: top of the second tier globally in PD-1/VEGF bispecifics (data generation-mate of ivonescimab, ~2 years behind in progress, but with Pfizer's channels and 8-9 Phase III breadth it is the "second candidate to arrive"); nephrology rhTPO category monopolist (60.4% share, slowly declining trend); dermatology leader with Metandi (~70%, generic influx is a medium-term threat); autoimmunity matrix (IL-17/IL-4R/IL-1β/IL-5) taking shape — the next BD out-licensing window. Sources of moat: 20 years of rhTPO process exclusivity + NRDL access; 85%+ gross-margin in-house manufacturing system; Pfizer-backed global clinical execution capability. Share trends are diverging: bispecific option value rising, rhEPO/Yisaipu declining, Metandi holding steady.
Pipeline panorama (2026-06-30, 25 key programs in development): Approved (3 Class I new drugs within 2026): 608 Yisaituo (IL-17A, psoriasis, 2026-02), SSS20 eltrombopag (ITP/SAA, 2026-03), 613 Yisaina (IL-1β, acute gout, 2026-08); NDA accepted: 611 (IL-4Rα, atopic dermatitis, accepted 2026-02, CRSwNP Phase III met primary endpoint), 601A (anti-VEGF, RVO, 2025-10), WS2403 semaglutide weight loss (2026-07); Phase III: 610 (IL-5, severe asthma, enrollment complete), WS204 (acne), 608 (AS/axSpA), TPIAO CLDT US bridging trial (FDA approval to proceed obtained 2026-07 — TPIAO's first overseas registration trial); Phase II: 705 (PD-1/HER2), 706 (PD-1/PD-L1), 627 (TL1A, UC), 626 (BDCA2, SLE); Phase I: SSS67 (ActRIIA/IIB fat-reduction/muscle-gain bispecific, US-China dual IND), etc.
Core asset rNPV (SSGJ-707, primary valuation anchor): Deal terms — upfront of USD 1.25 billion (received) + option/exercise payments up to USD 150 million + milestones up to USD 4.8 billion (approx. USD 4.68 billion remaining) + double-digit tiered royalties; Pfizer subscribed HKD 785 million in shares as alignment. Three-scenario rNPV (12% discount, USD 1 = RMB 6.6647):
| Scenario | Milestone realization rate | Peak sales | PoS | rNPV |
|---|---|---|---|---|
| Conservative | 20% | USD 0.9 billion | 60% | Approx. RMB 5.64 billion (USD 850 million) |
| Base | 35% | USD 3.0 billion (royalty 10.5%) | 70% | Approx. RMB 12.18 billion (USD 1.83 billion) |
| Bull | 50% | USD 5.0 billion (royalty 12.5%) | 75% | Approx. RMB 20.33 billion (USD 3.05 billion) |
SOTP (base case): Recurring business 10x × RMB 1.3 billion = RMB 13 billion + net cash RMB 17.97 billion + 707 base-case rNPV RMB 12.18 billion + autoimmunity/metabolic pipeline RMB 4 billion (expected value referencing domestic autoimmunity monoclonal BD upfronts of USD 50-200 million per asset) + Metandi spin-off re-rating option RMB 3 billion (theoretical valuation approx. RMB 8.7 billion × 60% execution/liquidity discount) = RMB 50.15 billion ≈ HKD 23.5/share, +55% vs current price; bear case total RMB 32.84 billion (HKD 15.4), bull case RMB 68.93 billion (HKD 32.3). Sensitivity anchors: each ±USD 1 billion in 707 peak sales moves rNPV by roughly ±RMB 3-4 billion (approx. ±HKD 1.4-1.9/share); each ±1pct royalty tier impacts ±HKD 0.9-1.5/share. Sell-side comparators: BOCOM International risk-adjusted peak of approx. USD 900 million (≈ conservative case); BofA 2035 risk-adjusted peak of approx. USD 5.6 billion (≈ above bull case) — our base case takes a position at the geometric midpoint, skewed conservative.
Clinical milestone calendar (binary events over the next 12-24 months):
Cash runway: Net cash of RMB 17.97 billion, annual R&D spend of approx. RMB 1.4-1.5 billion (fully expensed) + CapEx of RMB 1.0-1.2 billion over the next three years — a self-funded runway of 10+ years, no refinancing/dilution pressure (this is the fundamental difference from most loss-making biotechs: pipeline advancement does not depend on capital market sentiment).
Same-mechanism competitive standings: ① Ivonescimab (Akeso/Summit) — two approved indications in China, 60,000+ patients, defeated Keytruda head-to-head in HARMONi-2, FDA PDUFA 2026-11-14; global #1. ② 707 (Pfizer/3SBio) — Phase II ORR in the same tier as ivonescimab, broadest Phase III footprint (NSCLC/CRC/EC/UC, etc.), ~2 years behind; top of the global second tier. ③ BNT327 (BioNTech/BMS) — Phase III rollout across multiple tumor types; #3. ④ MK-2010 (Merck/LaNova) — Phase I/II, defensive posture. Risk coordinates: HARMONi-3 interim PFS previously failed to reach statistical significance (2026-04; Summit fell -25% in a single day), final readout in 2026Q4 — if it misses again, probability-of-success pricing for the entire赛道 will be revised down, and 707's milestone PoS and Pfizer's willingness to advance will be pressured simultaneously (corresponding to our bear-case scenario).
Verdict: Cautiously bullish, 12-18 months, confidence 0.58. 3SBio's investment case is a set of asymmetric odds: downside is supported by net cash (56% of market cap) and banked licensing proceeds; upside offers multiple falsifiable catalysts (milestone payments, NRDL negotiations, approvals, competitive data); the current price essentially prices in only the bear-case combination. Strategically, the current price suits phased position-building rather than a one-time heavy bet — the coming month (11-14 FDA decision, HARMONi-3 final readout window, year-end NRDL negotiation) is a high-beta two-way event period, and under the negative combination a drawdown to HKD 12-13 is a real possibility; for existing holders, holding and calibrating position sizes around event dates beats chasing rallies and selling dips. Core tracking list: ① incremental "licensing revenue" in interim/annual reports (direct evidence of milestone realization); ② the decline in biologics sales in the 2026 annual report (warning line -25%); ③ TPIAO sales share (a drop below 58% is a deterioration signal); ④ Pfizer EC/UC Phase III FPI and new milestones; ⑤ ChinaAMC's stake falling below 5% (a sign of clearing supply); ⑥ whether dividends/buybacks escalate into a systematic capital return framework (the precondition for convergence of the net-cash discount). Risk warnings: a failure in 707's global Phase III would simultaneously hit the milestone pool and the royalty option (the largest single valuation variable); if biologics erosion does not bottom, valuation could reset to HKD 10-13; FX gains/losses will continue to disturb reported profit; the Metandi spin-off carries uncertainty (prospectus lapsed 2026-05, not yet re-filed).